DAC: Degrader-Antibody Conjugates and Their Mechanisms

DAC: Degrader-Antibody Conjugates and Their Mechanisms

Introduction Degrader-antibody conjugates (DAC) are a novel entity that combines the payload of a proteolysis-targeting chimera (PROTAC) with monoclonal antibodies through a type of chemical linker (DAC = PROTAC + ADC). This article collects several examples of DAC from scientific and patent literature and records specific challenges associated with DAC construction. Overall, these examples indicate … Read more

Introduction to Antibody-Drug Conjugates (ADCs)

Introduction to Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more